DERM · CIK 0001867066 · operating
Based in Scottsdale, Arizona, Journey Medical Corporation develops and commercializes pharmaceutical products for dermatological conditions in the United States. The company's portfolio includes both branded and generic dermatology treatments addressing conditions such as hyperhidrosis, acne, rosacea, and fungal infections. Its marketed products comprise Qbrexza (medicated cloth towelette for axillary hyperhidrosis), Accutane (oral isotretinoin for severe acne), Amzeeq (topical minocycline for acne), Zilxi (topical minocycline for rosacea), Exelderm (antifungal treatment), Targadox (oral doxycycline for acne), and Emrosi (topical treatment for rosacea). The company also offers Luxamend, a topical wound care product designed to maintain moist healing environments for wounds, burns, and dermatological injuries.
Journey Medical operates as a specialty pharmaceutical company with a focused dermatology-oriented product line. The company maintains a lean organizational structure with approximately 41 full-time employees and operates primarily within the United States market. The company was incorporated in Delaware in 2014, succeeding from its prior entity, Coronado Dermatology, Inc.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.72 | $-0.72 | -242.9% | |
| 2023 | $-0.21 | $-0.21 | +87.6% | |
| 2022 | $-1.69 | $-1.69 | +60.9% | |
| 2021 | $-4.32 | $-4.32 | — |